The Policy:
On the 2nd April 2026, the Trump administration signed an executive order under Section 232 of the Trade Expansion Act, imposing a baseline 100% tariff on patented pharmaceutical products and active pharmaceutical ingredients (APIs) imported into the United States.
The Objective:
The stated goal is to bolster national security and supply chain resilience by forcing pharmaceutical companies to onshore manufacturing to the U.S. and opt into "most-favored-nation" (MFN) pricing agreements, which aim to match U.S. drug prices with lower international benchmarks.
Implementation Timelines:
The clock is currently ticking. Large pharmaceutical companies have 120 days to outline compliance plans, while small and mid-sized manufacturers have 180 days before the full 100% rate takes effect.
Country-Specific Impacts & Compliance Pathways
The tariff structure is not a blanket tax. It is heavily tiered based on existing international trade agreements and a company's willingness to build U.S. infrastructure:
100% Baseline: Applies to imports from nations without specific trade agreements if the manufacturer refuses to onshore production or negotiate pricing.
Reduced Rates via Trade Deals:
15% Tariff: Applies to imports from the European Union, Japan, South Korea, Switzerland, and Liechtenstein.
10% Tariff: Applies to imports from the United Kingdom (granted because the UK government agreed to raise its own pharmaceutical prices, allowing companies to lower U.S. prices).
The Onshoring Exemptions:
0% Tariff: Granted to companies that simultaneously build U.S. manufacturing facilities and sign MFN pricing agreements. (Currently, 13 major drugmakers have already signed these agreements).
20% Transitional Tariff: Granted to companies that commit to building domestic plants but have not signed MFN pricing agreements. This rate climbs back to 100% over a four-year period.
Impact on Dry Eye Products
For ocular health professionals and dry eye patients, this trade policy introduces significant market volatility regarding the cost and availability of specific therapeutics.
Branded Prescription Therapeutics:
Patented, brand-name dry eye treatments such as proprietary formulations of immunomodulators, novel tear-stimulating nasal sprays, or advanced topical corticosteroids that are manufactured overseas are the primary targets of this 100% tariff. If the parent companies do not secure U.S. manufacturing hubs or sign MFN agreements within the 120-to-180-day window, the cost of these imported branded medications could spike, or they may face supply chain bottlenecks at the pharmacy counter.The Generic Alternatives:
Crucially, generic drugs are explicitly exempt from these new tariffs for at least one year, at which point the policy will be reassessed. Patients relying on generic cyclosporine drops or standard generic topical antibiotics for lid margin disease are protected from immediate price rises.Over-the-Counter (OTC) Lubricants:
Many everyday artificial tears, lipid-based emulsions, and nighttime ointments will largely escape the 100% tariff if they are not classified as "patented" pharmaceuticals. However, if the raw active pharmaceutical ingredients (APIs) required for premium preservative-free drops are sourced internationally from non-exempt nations, manufacturers may still face supply chain friction, potentially passing fractional costs down to the consumer.
What This Means For You
If you are currently managing your dry eye disease with daily eye drops, this news might sound alarming, but there is no need to panic. The core takeaway is that the cost and availability of your treatment will depend heavily on the type of medication you use.
If you rely on a patented, brand-name prescription imported from overseas, you may see price increases or pharmacy delays in the coming months as manufacturers navigate these new 100% tariffs. However, if you use standard generic prescriptions or over-the-counter artificial tears, your daily routine and budget are largely protected from these immediate changes. The landscape of pharmaceutical pricing is shifting, but your options for effective dry eye management remain robust.
What You Should Do Next
To protect your ocular health and your wallet, take a proactive approach to your treatment plan over the next few weeks:
Audit Your Eye Drops: Take a look at the medications you use daily. Are they brand-name or generic? If you are unsure, a quick call to your pharmacist or a search online can clarify your medication's status.
Discuss Generic Alternatives: If you are using an expensive, imported branded drop, schedule a chat with your eye care professional. There are often highly effective, chemically similar generic alternatives that are explicitly exempt from these new tariffs.
Avoid Hoarding: While it is tempting to stock up, the pharmaceutical supply chain will take months to fully process these tariff impacts. Panic-buying can create artificial shortages that harm the broader dry eye community.
Explore In-Office Therapies: This is an excellent time to discuss procedural interventions with your doctor. Advanced in-office treatments such as Intense Pulsed Light (IPL) can address the root cause of meibomian gland dysfunction and can significantly reduce your long-term reliance on daily prescription eye drops.